Equities Analysts Issue Forecasts for BRTX FY2028 Earnings

BioRestorative Therapies, Inc. (NASDAQ:BRTX) – Equities researchers at Roth Capital cut their FY2028 earnings per share estimates for shares of BioRestorative Therapies in a report released on Monday, February 10th. Roth Capital analyst J. Aschoff now forecasts that the company will earn $5.24 per share for the year, down from their prior estimate of $5.40. The consensus estimate for BioRestorative Therapies’ current full-year earnings is ($1.43) per share. Roth Capital also issued estimates for BioRestorative Therapies’ FY2029 earnings at $6.93 EPS.

BioRestorative Therapies (NASDAQ:BRTX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.22. The firm had revenue of $0.23 million during the quarter, compared to analyst estimates of $0.30 million. BioRestorative Therapies had a negative return on equity of 98.49% and a negative net margin of 2,697.08%.

BioRestorative Therapies Price Performance

NASDAQ BRTX opened at $2.44 on Tuesday. BioRestorative Therapies has a 12 month low of $1.03 and a 12 month high of $2.55. The stock’s 50 day moving average is $1.79 and its 200 day moving average is $1.66.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.